Parametrica Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parametrica Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,221	Closed	-$570K	–	31
2023 Q3	$570K	Sell	3,221 -7,025	-69%	-$1.34M	0.96%	26
2023 Q2	$1.95M	Buy	10,246 +4,293	+72%	+$851K	3.75%	10
2023 Q1	$1.19M	Sell	5,953 -3,547	-37%	-$746K	2.15%	17
2022 Q4	$2.26M	Sell	9,500 -4,339	-31%	-$925K	4.63%	8
2022 Q3	$2.77M	Buy	+13,839	New	+$2.64M	5.66%	4
2018 Q4	–	Sell	-3,740	Closed	-$327K	–	260
2018 Q3	$327K	Buy	+3,740	New	+$376K	0.72%	45
2018 Q2	–	Sell	-5,928	Closed	-$706K	–	59
2018 Q1	$706K	Buy	+5,928	New	+$764K	0.87%	16
2016 Q2	–	Sell	-3,259	Closed	-$205K	–	205
2016 Q1	$205K	Buy	+3,259	New	+$217K	0.74%	81
2015 Q4	–	Sell	-2,962	Closed	-$238K	–	63
2015 Q3	$238K	Buy	+2,962	New	+$329K	1.5%	29

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Parametrica Management's ALNY Position: Q4 2023 in Review

Parametrica Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 3,221 shares — an estimated $570K sold.

Parametrica Management first reported a position in ALNY in Q3 2015 and held it in 9 quarters. The position peaked at $2.77M in Q3 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Parametrica Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Parametrica Management sold 3,221 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $570K.
Parametrica Management first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Parametrica Management's Alnylam Pharmaceuticals position peaked at $2.77M in Q3 2022.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Parametrica Management's 13F filing for Q4 2023, filed 2 Feb 2024.